Docosahexaenoic acid (DHA), a long-chain omega-3 polyunsaturated fatty acid (PUFA), is essential for neural development, cardiovascular protection, and anti-inflammation. Conventional fish-oil supply chains remain vulnerable to ecological pressure, compositional variability, and contaminants. Microbial production offers a controllable alternative, yet commercial feasibility depends on numerous factors beyond the strain yield. This review summarizes DHA-producing microorganisms and their metabolic pathways, including precursor supply, biosynthetic and storage pathways, and downstream separation and purification. Various separation strategies, ranging from crude lipid extraction to high-purity DHA, are evaluated in terms of recovery, selectivity, scale, cost, and oxidation risk. We discussed the synergistic mixed-fermentation and refining strategy that coproduces carotenoids, astaxanthin, and FAs to enhance the economic value. To achieve commercial competitiveness, a comprehensive approach combining metabolic engineering, fermentation optimization, and separation engineering is required to establish a microbial platform as an environmentally friendly and sustainable alternative to DHA from animal sources.
No takes yet. Share an insight, caveat, or question.
He et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: